Giovannoni G, et al. Treatment outcomes of daclizumab in patients at high risk of transitioning to secondary progressive multiple sclerosis in DECIDE. EAN 2107, O2113.
Vergoeding selumetinib (Koselugo) voor kinderen met neurofibromatose type 1
mei 2024